Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Rosuvastatin: Yellow Card reports provide early signal

    • 17 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      MHRA.Yellow Cards which made a difference - high-dose rosuvastatin and rhabdomyolysis. Drug Safety Update 5: Y1, No. 4, Nov 2011. Available from: URL: http://www.mhra.gov.uk

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Rosuvastatin: Yellow Card reports provide early signal. React. Wkly. 1380, 2 (2011). https://doi.org/10.2165/00128415-201113800-00003

    Download citation

    Keywords

    • Crestor
    • Rare Case
    • Safety Issue
    • Product Characteristic
    • Rosuvastatin